Symptom-triggered testing shows promise for identifying early-stage ovarian cancer

A recent International Journal of Gynecologic Cancer study evaluates the efficacy of symptom-triggered testing in detecting early-stage ovarian cancer.

Study: Symptom-triggered testing detects early stage and low volume resectable advanced stage ovarian cancer. Image Credit: Ground Picture / Shutterstock.com

Improving ovarian cancer patient outcomes

In the United Kingdom, ovarian cancer is the sixth most common cause of cancer-related deaths. Most women diagnosed with early-stage ovarian cancer, which is defined by the International Federation of Gynecology and Obstetrics (FIGO) as stage I or II, have better five-year survival rates as compared to women diagnosed with advanced stage ovarian cancer.

Clinical trials conducted in the U.K. and United States have demonstrated that screening for ovarian cancer can improve stage diagnosis but does not appear to significantly affect mortality rates. One key challenge that prevents the early diagnosis of ovarian cancer includes vague symptoms associated with this disease and its low prevalence rate.

Clinicians have identified a symptom triad that includes increased abdominal size and bloating, early satiety, and pain linked with ovarian cancer. Based on these symptoms, a symptom index was designed for national guidelines to increase awareness among clinicians.

Symptom-triggered testing for ovarian cancer has been endorsed by several U.K. and U.S.-based cancer organizations such as the American Cancer Society, Society of Gynecologic Oncology, and Foundation for Women’s Cancer. According to the U.S. National Institute for Health and Care Excellence (NICE), any woman should be referred to a gynecologist within two weeks of symptom detection. Thereafter, women should be tested for cancer antigen125 (CA125) levels and undergo a transvaginal ultrasound scan which, taken together, is referred to as a fast-track referral pathway.

Although the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) did not identify any benefit of ovarian cancer screening in reducing overall mortality rates, this screening approach has enabled the identification of women with high-grade serous ovarian cancer at stages I and II to ultimately improve short-term outcomes.

Early detection of ovarian cancer has the potential to increase the number of women receiving early treatments, such as surgery or adjuvant chemotherapy, which may ultimately improve survival rates.

About the study

The current descriptive study enrolled women who were recruited into Refining Ovarian Cancer Test accuracy Scores (ROCkeTS), an observational study designed to validate risk prediction models in pre- and post-menopausal women with suspected ovarian cancer. All women were diagnosed with high-grade serous ovarian cancer through the fast-track referral pathway.

Women between 16 and 90 years of age from different hospitals throughout the U.K. with high CA125 levels or/and abnormal imaging were considered for the study. All study participants completed a questionnaire at the beginning of the study and blood samples were collected to detect biomarkers.

The extent of the disease was classified as low, moderate, and high. Cytoreduction, which is defined as the residual tumor load, was also determined

Study findings

A total of 2,596 participants from ROCkeTS with a mean age of 63 years were recruited for the current study, 89.9% of whom were post-menopausal. Approximately 94% of women with high-grade serous ovarian cancer identified through the symptom-triggered fast-track pathway exhibited low-to-moderate disease spread and complete cytoreduction.

A complete cytoreduction or residual disease of one centimeter or less was achieved at surgery. Five patients did not receive any treatment.

The findings of the current study were consistent with the previously conducted DOvE pilot study, which revealed the possibility of high complete cytoreduction rates, even for patients with advanced high-grade serous ovarian cancer. The multimodal screening approach enabled the detection of a significant number of stage I and II high-grade epithelial ovarian cancer as compared with the ‘no screening’ arm, with detection rates of 25% and 14%, respectively.

Conclusions

The study findings indicate that about 25% of women with high-grade serous ovarian cancer, which is the most lethal subtype of ovarian cancer, can be detected at an early stage through the fast-track pathway following symptom-triggered testing. Symptom-triggered testing can efficiently detect women with low disease burden, potentially contribute to high complete cytoreduction rates, and may even improve survival outcomes in ovarian cancer patients.

There is a risk of selection bias in the present study, which is reflected in the observed stage distribution. Since the number of women recruited through the emergency pathway or from other outpatient referrals was modest, no statistically significant differences in performance status, disease stage, and cytoreduction rates were observed.

Journal reference:
  • Kwong, F. L. A., Kristunas, C., Davenport, C., et al. (2024) Symptom-triggered testing detects early stage and low volume resectable advanced stage ovarian cancer. International Journal of Gynecologic Cancerdoi:10.1136/ijgc-2024-005371
Dr. Priyom Bose

Written by

Dr. Priyom Bose

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bose, Priyom. (2024, August 19). Symptom-triggered testing shows promise for identifying early-stage ovarian cancer. News-Medical. Retrieved on October 03, 2024 from https://www.news-medical.net/news/20240819/Symptom-triggered-testing-shows-promise-for-identifying-early-stage-ovarian-cancer.aspx.

  • MLA

    Bose, Priyom. "Symptom-triggered testing shows promise for identifying early-stage ovarian cancer". News-Medical. 03 October 2024. <https://www.news-medical.net/news/20240819/Symptom-triggered-testing-shows-promise-for-identifying-early-stage-ovarian-cancer.aspx>.

  • Chicago

    Bose, Priyom. "Symptom-triggered testing shows promise for identifying early-stage ovarian cancer". News-Medical. https://www.news-medical.net/news/20240819/Symptom-triggered-testing-shows-promise-for-identifying-early-stage-ovarian-cancer.aspx. (accessed October 03, 2024).

  • Harvard

    Bose, Priyom. 2024. Symptom-triggered testing shows promise for identifying early-stage ovarian cancer. News-Medical, viewed 03 October 2024, https://www.news-medical.net/news/20240819/Symptom-triggered-testing-shows-promise-for-identifying-early-stage-ovarian-cancer.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insights into testosterone recovery after androgen deprivation therapy for prostate cancer